FDA to review Sarepta's Duchenne gene therapy for traditional approval

FDA to review Sarepta's Duchenne gene therapy for traditional approval

Submitted by admin on February 16, 2024 - 11:38am
Source: 
Reuters
News Tags: 
Sarepta Therapeutics
Duchenne Muscular Dystrophy
gene therapy
FDA
Elevidys
Headline: 
FDA to review Sarepta's Duchenne gene therapy for traditional approval
snippet: 

Sarepta Therapeutics (SRPT.O) said on Friday that the US FDA would review an application seeking traditional approval for its gene therapy to treat a muscle-wasting disorder by June 21, months after it failed the main goal of a confirmatory trial.

Do Not Allow Advertisers to Use My Personal information